SKIN · Company research
SkinHealth Systems Inc. Class A Common Stock (SKIN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
27records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| (SKIN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily | (SKIN) as a Liquidity Pulse for Institutional Tactics Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 19, 2026 | neutral | 0 | 0.6 |
| Canaccord initiates Quoin Pharmaceuticals stock at buy on rare skin disease drug potential - Investing.com | Canaccord initiates Quoin Pharmaceuticals stock at buy on rare skin disease drug potential Investing.com | View source ↗ | Investing.com | Oct 19, 2026 | neutral | 0 | 0.6 |
| MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits | MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| SkinHealth Systems Inc. (SKIN) Stock Price, News, Quote & History - Yahoo! Finance Canada | SkinHealth Systems Inc. (SKIN) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock? | SkinHealth Systems Inc. (SKIN) shares jumped 9% following completion of a 1-for-20 reverse stock split on October 14, 2026, which helped the company regain compliance with Nasdaq's minimum bid price requirement. However, the company faces significant headwinds with expected quarterly losses of $1.35 per share (down 1400% year-over-year) and revenues projected to decline 5% to $67.18 million. With no recent changes in earnings estimate revisions and a Zacks Rank #3 (Hold) rating, analysts question whether the recent rally can sustain. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 1 |
| SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock? | SkinHealth Systems Inc. (SKIN) shares jumped 9% following completion of a 1-for-20 reverse stock split on October 14, 2026, which helped the company regain compliance with Nasdaq's minimum bid price requirement. However, the company faces significant headwinds with expected quarterly losses of $1.35 per share (down 1400% year-over-year) and revenues projected to decline 5% to $67.18 million. With no recent changes in earnings estimate revisions and a Zacks Rank #3 (Hold) rating, analysts question whether the recent rally can sustain. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 1 |
| SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock? - Yahoo Finance | SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| Blackstone (BX) Stock Seems Reasonably Priced Following The ZO Skin Health Sale - Yahoo Finance | Blackstone (BX) Stock Seems Reasonably Priced Following The ZO Skin Health Sale Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Galderma agrees to buy ZO Skin Health and Galderma stock costs EUR 179.60 - ad-hoc-news.de | Galderma agrees to buy ZO Skin Health and Galderma stock costs EUR 179.60 ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 14, 2026 | neutral | 0 | 0.6 |
| Galderma signs ZO Skin Health deal: stock pre-market at EUR 180.73 - ad-hoc-news.de | Galderma signs ZO Skin Health deal: stock pre-market at EUR 180.73 ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 14, 2026 | neutral | 0 | 0.6 |
| FDA Staff Raise Concerns On Replimune’s Skin Cancer Drug – REPL Stock Crashes 32% Today Ahead Of Advisory Meeting This Week - Stocktwits | FDA Staff Raise Concerns On Replimune’s Skin Cancer Drug – REPL Stock Crashes 32% Today Ahead Of Advisory Meeting This Week Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| 78% of Gen Z says stress affects their skin. e.l.f. offers a $12 soothing mist. - Stock Titan | 78% of Gen Z says stress affects their skin. e.l.f. offers a $12 soothing mist. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Hydrafacial Introduces HydraClear™ Treatment Booster to Clarify Blemish-Prone Skin | SkinHealth Systems announced the launch of HydraClear Treatment Booster, a triple-acid formula designed to clarify and balance blemish-prone skin. Clinical trials showed a 38% mean reduction in total blemishes after four treatments, with 81% of participants showing fewer visible blemishes. The product will be integrated into Deluxe and Platinum Hydrafacial treatments. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Hydrafacial Introduces HydraClear™ Treatment Booster to Clarify Blemish-Prone Skin | SkinHealth Systems announced the launch of HydraClear Treatment Booster, a triple-acid formula designed to clarify and balance blemish-prone skin. Clinical trials showed a 38% mean reduction in total blemishes after four treatments, with 81% of participants showing fewer visible blemishes. The product will be integrated into Deluxe and Platinum Hydrafacial treatments. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| A new Hydrafacial booster targets blemishes; 81% of participants showed fewer visible blemishes. - Stock Titan | A new Hydrafacial booster targets blemishes; 81% of participants showed fewer visible blemishes. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| SkinHealth Systems bringt das SkinStylus® SteriLock® MicroSystem auf den europäischen Markt | SkinHealth Systems (Nasdaq: SKIN) announced the European launch of SkinStylus® SteriLock® MicroSystem, a professional micro- and nano-needling device, now available in the UK, Ireland, Germany, France, Spain, and Portugal. The expansion leverages the company's established Hydrafacial distribution network and aims to offer complementary aesthetic solutions to practitioners across the region. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| Le SkinStylus® SteriLock MicroSystem de SkinHealth Systems désormais disponible sur le marché européen | SkinHealth Systems announced the European launch of SkinStylus® SteriLock MicroSystem, a professional microneedling and nanoneedling device, across the UK, Ireland, Germany, France, Spain, and Portugal. The expansion leverages the company's established Hydrafacial® network and represents a strategic move to offer complementary aesthetic solutions beyond its core skincare offerings. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| SkinHealth Systems Expands SkinStylus® SteriLock® MicroSystem to Europe | SkinHealth Systems announced the European expansion of its SkinStylus SteriLock MicroSystem, a professional microneedling and nano-needling device, across the UK, Ireland, Germany, France, Spain and Portugal. The company will leverage its established Hydrafacial commercial organization and provider relationships to introduce the complementary technology to aesthetic professionals in the region. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| SkinHealth Systems anuncia el lanzamiento europeo de SkinStylus® SteriLock® | SkinHealth Systems announced the European expansion of its SkinStylus SteriLock MicroSystem, a professional microneedling and nano-needling device, now available in the UK, Ireland, Germany, France, Spain, and Portugal. The company will leverage Hydrafacial's established European distribution network to market the complementary technology to aesthetic professionals, supporting its strategy to build a broader medical aesthetics ecosystem. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| SKIN: Stockholders voted on a reverse stock split and adjournment, with results to be filed in Form 8-K - TradingView | SKIN: Stockholders voted on a reverse stock split and adjournment, with results to be filed in Form 8-K TradingView | View source ↗ | TradingView | Sep 22, 2026 | neutral | 0 | 0.6 |
| Topical skin treatment back in stock - Vet Times | Topical skin treatment back in stock Vet Times | View source ↗ | Vet Times | Sep 7, 2026 | neutral | 0 | 0.6 |
| Nu Skin (NUS) Stock Sinks After Impairment Fueled Loss Deepens - Simply Wall Street | Nu Skin (NUS) Stock Sinks After Impairment Fueled Loss Deepens Simply Wall Street | View source ↗ | Simply Wall Street | Aug 11, 2026 | neutral | 0 | 0.6 |
| SkinHealth Systems Inc. (SKIN) Stock Falls on Q2 2026 Earnings - Quiver Quantitative | SkinHealth Systems Inc. (SKIN) Stock Falls on Q2 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 6, 2026 | neutral | 0 | 0.6 |
| Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment - Investor's Business Daily | Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment Investor's Business Daily | View source ↗ | Investor's Business Daily | Jul 9, 2026 | neutral | 0 | 0.6 |
| SKIN Stock Pops On Volume As Balance Sheet Draws Focus - StocksToTrade | SKIN Stock Pops On Volume As Balance Sheet Draws Focus StocksToTrade | View source ↗ | StocksToTrade | Jul 7, 2026 | neutral | 0 | 0.6 |
| Nu Skin (NUS) Soars 6.9%: Is Further Upside Left in the Stock? - Yahoo Finance | Nu Skin (NUS) Soars 6.9%: Is Further Upside Left in the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 29, 2026 | neutral | 0 | 0.6 |
| How The Beauty Health (SKIN) Investment Story Is Shifting With Mixed Analyst Signals - Yahoo Finance | How The Beauty Health (SKIN) Investment Story Is Shifting With Mixed Analyst Signals Yahoo Finance | View source ↗ | Yahoo Finance | Apr 8, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.